Lexeo Therapeutics Inc (LXEO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -42,920 | -21,682 | -66,394 | -52,207 | -32,099 |
| Depreciation Amortization | 146 | 69 | 271 | 194 | 116 |
| Accounts payable and accrued liabilities | 1,698 | 639 | -180 | -574 | -864 |
| Other Working Capital | 1,752 | 4,008 | 1,482 | 2,828 | -1,726 |
| Other Operating Activity | 4,305 | 2,099 | 5,325 | 4,244 | 3,007 |
| Operating Cash Flow | $-35,019 | $-14,867 | $-59,496 | $-45,515 | $-31,566 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -398 | -185 | -115 | -42 | -39 |
| Purchase Sale Intangibles | -13 | -8 | -50 | -50 | N/A |
| Other Investing Activity | -13 | -8 | -50 | -50 | 0 |
| Investing Cash Flow | $-411 | $-193 | $-165 | $-92 | $-39 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | 4,000 | 4,000 | N/A |
| Debt Repayment | -183 | -109 | -425 | -320 | -213 |
| Common Stock Issued | 95,428 | 88,763 | 100,302 | 51 | 21 |
| Common Stock Repurchased | -13 | N/A | N/A | N/A | N/A |
| Other Financing Activity | -6,287 | 0 | -86 | -11 | 0 |
| Financing Cash Flow | $88,945 | $88,654 | $103,791 | $3,720 | $-192 |
| Beginning Cash Position | 124,718 | 124,718 | 80,588 | 80,588 | 80,588 |
| End Cash Position | 178,233 | 198,312 | 124,718 | 38,701 | 48,791 |
| Net Cash Flow | $53,515 | $73,594 | $44,130 | $-41,887 | $-31,797 |
| Free Cash Flow | |||||
| Operating Cash Flow | -35,019 | -14,867 | -59,496 | -45,515 | -31,566 |
| Capital Expenditure | -398 | -185 | -115 | -42 | -39 |
| Free Cash Flow | -35,417 | -15,052 | -59,611 | -45,557 | -31,605 |